JPMorgan analyst Chris Schott raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $14 from $12 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but increased price targets on a move to December 2026 from December 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals receives FDA approval of sodium oxybate oral solution
- Amneal gets FDA approval for risperidone extended-release injectable suspension
- Amneal Pharma Reports Strong Q2 2025 Results
- Amneal Pharma’s Optimistic Q2 Earnings Call Highlights
- Knight Therapeutics announces CREXONT regulatory submission in Mexico